Deregulation of miR-146a expression in a mouse model of pancreatic cancer affecting EGFR signaling

Cancer Letters

Volumn 351, Issue 1, 2014, Pages 134-142

  Ali, Shadan ^a   Ahmad, Aamir ^a   Aboukameel, Amro ^a   Ahmed, Alia ^a   Bao, Bin ^a   Banerjee, Sanjeev ^a   Philip, Philip A ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CDF; EGFR; MiR 146a; Pancreatic cancer; Xenograft mouse model

Indexed keywords

ARF PROTEIN; CRE RECOMBINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; INK4A PROTEIN; K RAS PROTEIN; LUCIFERASE; MICRORNA 146A; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN SERINE THREONINE KINASE INHIBITOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR PDX 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CARCINOGENESIS; CELL MIGRATION; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALIA; MUS; MUS MUSCULUS;

CDF; EGFR; MIR-146A; PANCREATIC CANCER; XENOGRAFT MOUSE MODEL;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CURCUMIN; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, SCID; MICE, TRANSGENIC; MICRORNAS; NEOPLASM TRANSPLANTATION; PANCREAS; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR BURDEN;

EID: 84903699121     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.05.013     Document Type: Article

References (38)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63(2013):11-30.
2. Ali S., Almhanna K., Chen W., Philip P.A., Sarkar F.H. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am. J. Transl. Res. 2010, 3:28-47.
3. Ali S., Saleh H., Sethi S., Sarkar F.H., Philip P.A. MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer. Br. J. Cancer 2012, 107:1354-1360.
4. Ali S., Banerjee S., Logna F., Bao B., Philip P.A., Korc M., Sarkar F.H. Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. J. Cell. Physiol. 2012, 227:3373-3380.
5. Bao B., Ali S., Banerjee S., Wang Z., Logna F., Azmi A.S., Kong D., Ahmad A., Li Y., Padhye S., Sarkar F.H. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res. 2012, 72:335-345.
6. Li Y., Vandenboom T.G., Wang Z., Kong D., Ali S., Philip P.A., Sarkar F.H. MiR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 2010, 70:1486-1495.
7. Mei J., Bachoo R., Zhang C.L. MicroRNA-146a inhibits glioma development by targeting Notch1. Mol. Cell. Biol. 2011, 31:3584-3592.
8. Paik J.H., Jang J.Y., Jeon Y.K., Kim W.Y., Kim T.M., Heo D.S., Kim C.W. MicroRNA-146a downregulates NFkappaB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma. Clin. Cancer Res. 2011, 17:4761-4771.
9. Chassin C., Hempel C., Stockinger S., Dupont A., Kubler J.F., Wedemeyer J., Vandewalle A., Hornef M.W. MicroRNA-146a-mediated downregulation of IRAK1 protects mouse and human small intestine against ischemia/reperfusion injury. EMBO Mol. Med. 2012, 4:1308-1319.
10. de la Chapelle A., Jazdzewski K. MicroRNAs in thyroid cancer. J. Clin. Endocrinol. Metab. 2011, 96:3326-3336.
11. Garcia A.I., Buisson M., Bertrand P., Rimokh R., Rouleau E., Lopez B.S., Lidereau R., Mikaelian I., Mazoyer S. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol. Med. 2011, 3:279-290.
12. Chen G., Umelo I.A., Lv S., Teugels E., Fostier K., Kronenberger P., Dewaele A., Sadones J., Geers C., De G.J. MiR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS One 2013, 8:e60317.
13. Shen J., Xia W., Khotskaya Y.B., Huo L., Nakanishi K., Lim S.O., Du Y., Wang Y., Chang W.C., Chen C.H., Hsu J.L., Wu Y., Lam Y.C., James B.P., Liu X., Liu C.G., Patel D.J., Hung M.C. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 2013, 497:383-387.
14. Xu B., Wang N., Wang X., Tong N., Shao N., Tao J., Li P., Niu X., Feng N., Zhang L., Hua L., Wang Z., Chen M. MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. Prostate 2012, 72:1171-1178.
15. Ali S., Ahmad A., Banerjee S., Padhye S., Dominiak K., Schaffert J.M., Wang Z., Philip P.A., Sarkar F.H. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 2010, 70:3606-3617.
16. Bao B., Ali S., Kong D., Sarkar S.H., Wang Z., Banerjee S., Aboukameel A., Padhye S., Philip P.A., Sarkar F.H. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One 2011, 6:e17850.
17. Padhye S., Yang H., Jamadar A., Cui Q.C., Chavan D., Dominiak K., McKinney J., Banerjee S., Dou Q.P., Sarkar F.H. New difluoro Knoevenagel condensates of curcumin, their Schiff bases and copper complexes as proteasome inhibitors and apoptosis inducers in cancer cells. Pharm. Res. 2009, 26:1874-1880.
18. Padhye S., Banerjee S., Chavan D., Pandye S., Swamy K.V., Ali S., Li J., Dou Q.P., Sarkar F.H. Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm. Res. 2009, 26:2438-2445.
19. Carriere C., Young A.L., Gunn J.R., Longnecker D.S., Korc M. Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. Biochem. Biophys. Res Commun. 2009, 382:561-565.
20. Seeley E.S., Carriere C., Goetze T., Longnecker D.S., Korc M. Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia. Cancer Res. 2009, 69:422-430.
21. Ali S., El-Rayes B.F., Sarkar F.H., Philip P.A. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol. Cancer Ther. 2005, 4:1943-1951.
22. Ali S., Ahmad A., Aboukameel A., Bao B., Padhye S., Philip P.A., Sarkar F.H. Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells. Cancer Lett. 2012, 319:173-181.
23. Soubani O., Ali A.S., Logna F., Ali S., Philip P.A., Sarkar F.H. Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. Carcinogenesis 2012, 33:1563-1571.
24. Ahmad A., Sarkar S.H., Aboukameel A., Ali S., Biersack B., Seibt S., Li Y., Bao B., Kong D., Banerjee S., Schobert R., Padhye S.B., Sarkar F.H. Anticancer action of garcinol in vitro and in vivo is in part mediated through inhibition of STAT-3 signaling. Carcinogenesis 2012, 33:2450-2456.
25. Pryczynicz A., Guzinska-Ustymowicz K., Czyzewska J., Kemona A. Expression of epidermal growth factors and apoptosis markers in pancreatic ductal adenocarcinoma. Folia Histochem. Cytobiol. 2009, 47:667-671.
26. Weiss G.A., Rossi M.R., Khushalani N.I., Lo K., Gibbs J.F., Bharthuar A., Cowell J.K., Iyer R. Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma. J. Gastrointest. Oncol. 2013, 4:20-29.
27. Muslimov G.F. Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma. Bull. Exp. Biol. Med. 2008, 145:535-538.
28. Barr S., Thomson S., Buck E., Russo S., Petti F., Sujka-Kwok I., Eyzaguirre A., Rosenfeld-Franklin M., Gibson N.W., Miglarese M., Epstein D., Iwata K.K., Haley J.D. Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin. Exp. Metastasis 2008, 25:685-693.
29. Miyabayashi K., Ijichi H., Mohri D., Tada M., Yamamoto K., Asaoka Y., Ikenoue T., Tateishi K., Nakai Y., Isayama H., Morishita Y., Omata M., Moses H.L., Koike K. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Cancer Res. 2013, 73:2221-2234.
30. Walters D.M., Lindberg J.M., Adair S.J., Newhook T.E., Cowan C.R., Stokes J.B., Borgman C.A., Stelow E.B., Lowrey B.T., Chopivsky M.E., Gilmer T.M., Parsons J.T., Bauer T.W. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib. Neoplasia 2013, 15:143-155.
31. Li L., Chen X.P., Li Y.J. MicroRNA-146a and human disease. Scand. J. Immunol. 2010, 71:227-231.
32. Yao Q., Cao Z., Tu C., Zhao Y., Liu H., Zhang S. MicroRNA-146a acts as a metastasis suppressor in gastric cancer by targeting WASF2. Cancer Lett. 2013, 335:219-224.
33. Hou Z., Xie L., Yu L., Qian X., Liu B. MicroRNA-146a is down-regulated in gastric cancer and regulates cell proliferation and apoptosis. Med. Oncol. 2012, 29:886-892.
34. Li X., Xu B., Moran M.S., Zhao Y., Su P., Haffty B.G., Shao C., Yang Q. 53BP1 Functions as a tumor suppressor in breast cancer via the inhibition of NF-kappaB through miR-146a. Carcinogenesis 2012, 33:2593-2600.
35. Bloomston M., Bhardwaj A., Ellison E.C., Frankel W.L. Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig. Surg. 2006, 23:74-79.
36. Xiong H.Q., Rosenberg A., LoBuglio A., Schmidt W., Wolff R.A., Deutsch J., Needle M., Abbruzzese J.L. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J. Clin. Oncol. 2004, 22:2610-2616.
37. Qin C.F., Hao K., Tian X.D., Xie X.H., Yang Y.M. Combined effects of EGFR and Hedgehog signaling pathway inhibition on the proliferation and apoptosis of pancreatic cancer cells. Oncol. Rep. 2012, 28:519-526.
38. Chang Z.G., Wei J.M., Qin C.F., Hao K., Tian X.D., Xie K., Xie X.H., Yang Y.M. Suppression of the epidermal growth factor receptor inhibits epithelial-mesenchymal transition in human pancreatic cancer PANC-1 cells. Dig. Dis. Sci. 2012, 57:1181-1189.